Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Review
  • Published:

International childhood Acute Lymphoblastic Leukemia workshop: Sausalito, CA, 30 November–1 December 2000

Leukemia volume 15, pages 707–715 (2001)Cite this article

As the cure rate of childhood acute lymphoblastic leukemia (ALL) approaches 80%,1 international collaboration is required to facilitate further treatment advances. During the 27th Annual Meeting of the International Society of Pediatric Oncology (SIOP) in 1995, representatives of several study groups and institutions agreed to first focus the efforts on high-risk genetic subgroups.2 This initiative was quickly joined by virtually all major study groups and institutions in Europe and the United States. The first collaboration resulted in a consensus on the management of patients with Philadelphia chromosome-positive (Ph+) ALL.3 To facilitate these collaborations, two workshops were held, one at the St Jude Children's Research Hospital (SJCRH) in 1997 and the other in Ponte di Legno, Italy in 1999. The meeting report of the first workshop has been published in this journal.4 During the second workshop, the participants agreed to report updated long-term results of clinical trials conducted in the 1980s and 1990s, using uniform criteria and format. The intent was to identify effective treatment for certain well-defined subsets of patients. This unprecedented effort resulted in 12 informative articles published together in the December 2000 issue of Leukemia,5678910111213141516 providing valuable clues to advance the cure rate in future trials.

The third international Childhood ALL Workshop organized by C-H Pui, S Sallan, MV Relling, and WE Evans was held on 30 November and 1 December 2000 in Sausalito, California, and attended by representatives from 12 study groups or institutions (see appendix). After the participants were welcomed by the organizers, G Masera provided the historical perspective of the workshop and acknowledged the importance and spirit of the international collaboration.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Pui C-H, Evans WE . Acute lymphoblastic leukemia N Eng J Med 1998 339: 605–615

    CAS  Google Scholar 

  2. Schrappe M, Camitta B, Pui C-H on behalf of Eden T, Gaynon P, Gustafsson G, Janka-Schaub GE, Kamps W, Masera G, Sallan S, Tsuchida M, Vilmer E . Long-term results of large prospective trials in childhood acute lymphoblastic leukemia Leukemia 2000 14: 2193–2194

    CAS  PubMed  Google Scholar 

  3. Aricò M, Valsecchi MG, Camitta B, Schrappe M, Chessells J, Baruchel A, Gaynon P, Silverman L, Janka-Schaub G, Kamps W, Pui C-H, Masera G . Outcome of treatment in children with Philadelphia chromosome-positive acute lymphoblastic leukemia N Engl J Med 2000 342: 998–1006

    PubMed  Google Scholar 

  4. Pui C-H, Evans WE, Gilbert JR . Meeting report: International Childhood ALL Workshop, Memphis, TN, 3–4 December 1997 Leukemia 1998 12: 1313–1318

    CAS  PubMed  Google Scholar 

  5. Conter V, Aricò M, Valsecchi MG, Basso G, Biondi A, Madon E, Mandelli F, Paolucci G, Pession A, Rizzari C, Rondelli R, Zanesco L, Masera G for the Associazione Italiana di Ematologia ed Oncologia Pediatrica (AIEOP) . Long-term results of the Italian Association of Pediatric Hematology and Oncology (AIEOP) acute lymphoblastic leukemia studies, 1982–1995 Leukemia 2000 14: 2196–2204

    CAS  PubMed  Google Scholar 

  6. Schrappe M, Reiter A, Zimmermann M, Harbott J, Ludwig W-D, Henze G, Gadner H, Odenwald, Riehm H . Long-term results of four consecutive trials in childhood ALL performed by the ALL-BFM study group from 1981 to 1995 Leukemia 2000 14: 2205–2222

    CAS  PubMed  Google Scholar 

  7. Gaynon PS, Trigg ME, Heerema NA, Sensel MG, Sather HN, Hammond GD, Blayer WA . Children's Cancer Group trials in childhood acute lymphoblastic leukemia: 1983–1995 Leukemia 2000 14: 2223–2233

    CAS  PubMed  Google Scholar 

  8. Harms DO, Janka-Schaub GE on behalf of the COALL Study Group . Co-operative study group for childhood acute lymphoblastic leukemia (COALL): long-term follow-up of trials 82, 85, 89 and 92 Leukemia 2000 14: 2234–2239

    CAS  PubMed  Google Scholar 

  9. Kamps WA, Veerman AJP, van Wering ER, van Weerden JF, Slater R, van der Does-van den Berg A . Long-term follow-up of Dutch Childhood Leukemia Study Group (DCLSG) protocols for children with acute lymphoblastic leukemia, 1984–1991 Leukemia 2000 14: 2240–2246

    CAS  PubMed  Google Scholar 

  10. Silverman LB, Declerck L, Gelber RD, Kimball Dalton V, Asselin BL, Barr RD, Clavell LA, Hurwitz CA, Moghrabi A, Samson Y, Schorin MA, Lipton JM, Cohen HJ, Sallan SE . Results of Dana-Farber Cancer Institute Consortium protocols for children with newly diagnosed acute lymphoblastic leukemia (1981–1995) Leukemia 2000 14: 2247–2256

    CAS  PubMed  Google Scholar 

  11. Vilmer E, Suciu S, Ferster A, Bertrand Y, Cavé H, Thyss A, Benoit Y, Dastugue N, Fournier M, Souillet G, Manel A-M, Robert A, Nelken B, Millot F, Lutz P, Rialland X, Mechinaud F, Boutard P, Behar C, Chantraine J-M, Plouvier E, Laureys G, Brock P, Uyttebroeck A, Margueritte G, Plantaz D, Norton L, Francotte N, Gyselinck J, Waterkeyn C, Solbu G, Philippe N, Otten J . Long-term results of three randomized trials (58831, 58832, 58881) in childhood acute lymphoblastic leukemia: a CLCG-EORTC report Leukemia 2000 14: 2257–2266

    CAS  PubMed  Google Scholar 

  12. Gustafsson G, Schmiegelow K, Forestier E, Clausen N, Glomstein A, Jonmundsson G, Mellander L, Mäkipernaa A, Nygaard R, Saarinen-Pihkala UM on behalf of the Nordic Society of Pediatric Haematology and Oncology (NOPHO) . Improving outcome through two decades in childhood ALL in the Nordic countries: the impact of high-dose methotrexate in the reduction of CNS irradiation Leukemia 2000 14: 2267–2275

    CAS  PubMed  Google Scholar 

  13. Maloney KW, Shuster JJ, Murphy S, Pullen J, Camitta BA . Long-term results of treatment studies for childhood acute lymphoblastic leukemia: Pediatric Oncology Group studies from 1986–1994 Leukemia 2000 14: 2276–2285

    CAS  PubMed  Google Scholar 

  14. Pui C-H, Boyett JM, Rivera GK, Hancock ML, Sandlund JT, Ribeiro RC, Rubnitz JE, Behm FG, Raimondi SC, Gajjar A, Razzouk B, Campana D, Kun LE, Relling MV, Evans WE . Long-term results of Total Therapy studies 11, 12 and 13A for childhood acute lymphoblastic leukemia at St Jude Children's Research Hospital Leukemia 2000 14: 2286–2294

    CAS  PubMed  Google Scholar 

  15. Tsuchida M, Ikuta K, Hanada R, Saito T, Isoyama K, Sugita K, Toyoda Y, Manabe A, Koike K, Kinoshita A, Maeda M, Ishimoto K, Sato T, Okimoto Y, Kaneko T, Kajiwara M, Sotomatsu M, Hayashi Y, Yabe H, Hosoya R, Hoshi Y, Ohira M, Bessho F, Tsunematsu Y, Tsukimoto I, Nakazawa S, for the Tokyo Children's Cancer Study Group . Long-term follow-up of childhood acute lymphoblastic leukemia in Tokyo Children's Cancer Study Group 1981–1995 Leukemia 2000 14: 2295–2306

    CAS  PubMed  Google Scholar 

  16. Eden OB, Harrison G, Richards S, Lilleyman JS, Bailey CC, Chessells JM, Hann IM . Hill FGH, Gibson BES on behalf of the Medical Research Council Childhood Leukaemia Working Party Leukemia 2000 14: 2307–2320

    CAS  PubMed  Google Scholar 

  17. Harbott J, Heerema NA, Baruchel A, Camitta BM, Chessells JM, Gaynon PS, Janka-Schaub G, Pui C-H, Sallan SE, Schrappe M, Valsecchi MG, Aricò M . Secondary chromosomal aberrations in 255 childhood cases of Ph-positive acute lymphoblastic leukemia (ALL) Blood 2000 96: (Suppl. 1) 710a

    Google Scholar 

  18. Talpaz M, Sawyers CL, Kantarjain D, Resta S, Fernandes Reese S, Ford J, Druker BJ . Activity of an ABL specific tyrosine kinase inhibitor in patients with BCR-ABL positive acute leukemias, including chronic myelogenous leukemia in blasts crisis Proc Am Soc Clin Oncol 2000 19: 4a

    Google Scholar 

  19. Fang G, Kim CN, Perkins CL, Ramadevi N, Winton E, Wittmann S, Bhalla KN . CGP57148B (STI-571) induces differentiation and apoptosis and sensitizes Bcr-ABL positive human leukemia cells to apoptosis due to antileukemic drugs Blood 2000 96: 2246–2253

    CAS  PubMed  Google Scholar 

  20. Thiesing JT, Ohno-Jones S, Kolibaba KS, Druker BJ . Efficacy of STI571, an Abl tyrosine kinase inhibitor, in conjunction with other antileukemic agents against Bcr-Abl-positive cells Blood 2000 96: 3195–3199

    CAS  PubMed  Google Scholar 

  21. Talpaz M, Silver RT, Bruker B, Paquette R, Goldman JM, Reese SF, Capdeville R . A phase II study of STI 571 in adult patients with Philadelphia chromosome positive chronic myeloid leukemia in accelerated phase Blood 2000 96: (Suppl. 1) 469a

    Google Scholar 

  22. Sawyers C, Hochhaus A, Feldman E, Goldman JM, Miller C, Ben-Am M, Candeville R, Druker B . A phase II study to determine the safety and anti-leukemic effects of STI571 in patients with Philadelphia chromosome positive chronic myeloid leukemia in myeloid blast crisis Blood 2000 96: (Suppl. 1) 503a

    Google Scholar 

  23. Raimondi SC, Frestedt JL, Pui C-H, Downing JR, Head DR, Kersey JH, Behm FG . Acute lymphoblastic leukemias with deletion of 11q23 or a novel inversion (11)(p13q23) lack MLL gene rearrangements and have favorable clinical features Blood 1995 86: 1881–1886

    CAS  PubMed  Google Scholar 

  24. Rubnitz JE, Camitta BM, Mahmoud H, Raimondi SC, Carroll AJ, Borowitz MJ, Shuster JJ, Link MP, Pullen DJ, Downing JR, Behm FG, Pui C-H . Childhood acute lymphoblastic leukemia with the MLL-ENL fusion and t(11;19)(q23;p13.3) translocation J Clin Oncol 1999 17: 191–196

    CAS  PubMed  Google Scholar 

  25. Pui C-H, Frankel LS, Carroll AJ, Raimondi SC, Shuster JJ, Head DR, Crist WM, Land VJ, Pullen DJ, Steuber CP, Behm FG, Borowitz MJ . Clinical characteristics and treatment outcome of childhood acute lymphoblastic leukemia with the t(4;11)(q21;q23): a collaborative study of 40 cases Blood 1991 77: 440–447

    CAS  PubMed  Google Scholar 

  26. Johansson B, Moorman AV, Haas OA, Watmore AE, Cheung KL, Swanton S, Seeker-Walker LM, on behalf of the European 11q23 Workshop participants . Hematologic malignancies with t(4;11)(q21;q23) – a cytogenetic, morphologic, immunophenotypic and clinical study of 183 cases Leukemia 1998 12: 779–787

    CAS  PubMed  Google Scholar 

  27. Dördelmann M, Reiter A, Borkhardt A, Ludwig W-D, Götz N, Viehmann S, Gadner H, Riehm H, Schrappe M for the ALL-BFM Group . Prednisone response is the strongest predictor of treatment outcome in infant acute lymphoblastic leukemia Blood 1999 94: 1209–1217

    PubMed  Google Scholar 

  28. Vera A, Will A, Reid M, Lilleyman J, McDonald-Clink J, Chessells J . Assessment of early response to induction therapy lacks prognostic significance in infant acute lymphoblastic leukemia Blood 2000 96: (Suppl. 1) 463a

    Google Scholar 

  29. Stevens RF, Hann IM, Wheatley K, Gray RG on behalf of the MRC Childhood Leukaemia Working Party . Marker improvements in outcome with chemotherapy alone in paediatric acute myeloid leukaemia: results of the United Kingdom Medical Research Council's 10th AML trial Br J Haematol 1998 101: 130–140

    CAS  PubMed  Google Scholar 

  30. van der Burg M, Beverloo HB, Langerak AW, Wijsman J, van Drunen E, Slater R, van Dongen JJM . Rapid and sensitive detection of all types of MLL gene translocations with a single FISH probe set Leukemia 1999 13: 2107–2113

    CAS  PubMed  Google Scholar 

  31. Pui C-H, Carroll AJ, Head D, Raimondi SC, Shuster JJ, Crist WM, Link MP, Borowitz MJ, Behm FG, Land VJ, Nash MB, Pullen DJ, Look AT . Near-triploid and near-tetraploid acute lymphoblastic leukemia of childhood Blood 1990 76: 590–596

    CAS  PubMed  Google Scholar 

  32. Raimondi SC, Shurtleff SA, Mathew S, Rubnitz JE, Hancock ML, Rivera GK, Pui C-H, Behm FG . Hyperdiploidy of more than 69 chromosomes is strongly associated with the TEL-AML1 fusion and favorable outcome for children with B-lineage ALL Blood 1999 94: (Suppl 1) 502a

    Google Scholar 

  33. Pui C-H, Carroll AJ, Raimondi SC, Land VJ, Crist WM, Shuster JJ, Williams DL, Pullen DJ, Borowitz MJ, Behm FG, Look AT . Clinical presentation, karyotypic characterization, and treatment outcome of childhood acute lymphoblastic leukemia with a near-haploid or hypodiploid <45 line Blood 1990 75: 1170–1177

    CAS  PubMed  Google Scholar 

  34. Heerema NA, Nachman JB, Sather HN, Sensel MG, Lee MK, Hutchinson R, Lange BJ, Steinherz PG, Bostrom B, Gaynon PS, Uckun F . Hypodiploidy with less than 45 chromosomes confers adverse risk in childhood acute lymphoblastic leukemia: a report from the Children's Cancer Group Blood 1999 94: 4036–4046

    CAS  PubMed  Google Scholar 

  35. Hanger SP . Chromosomal translocations involving the E2A gene in acute lymphoblastic leukemia: clinical features and molecular pathogenesis Blood 1996 87: 1211–1224

    Google Scholar 

  36. Coustan-Smith E, Behm FG, Sanchez J, Boyett JM, Hancock ML, Raimondi SC, Rubnitz JE, Rivera GK, Sandlund JT, Pui C-H, Campana D . Immunological detection of minimal residual disease in children with acute lymphoblastic leukaemia Lancet 1998 351: 550–554

    CAS  PubMed  Google Scholar 

  37. Cavé H, van der Werfften Bosch J, Suciu S, Guidal C, Waterkeyn C, Otten J, Bakkus M, Thielemans K, Granchamp B, Vilmer E . Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia N Engl J Med 1998 339: 591–598

    PubMed  Google Scholar 

  38. van Dongen JJM, Seriu T, Panzer-Grümayer ER, Biondi A, Pongers-Willemse MJ, Corral L, Stolz F, Schrappe M, Masera G, Kamps WA, Gadner H, van Wering ER, Ludwig W-D, Basso G, de Bruijn MAC, Cazzaniga G, Hettinge K, van der Does-van den Berg A, Hop WCJ, Riehm H, Bartram CR . Prognostic value of minimal residual disease in acute lymphoblastic leukaemia in childhood Lancet 1998 352: 1731–1738

    CAS  PubMed  Google Scholar 

  39. Verhagen OJHM, Willemse MJ, Breunis WB, Wijkhuijs AJM, Jacobs DCH, van Wering ER, van Dongen JJM, van der Schoot CE . Application of germline IGH probes in real-time quantitative PCR for the detection of minimal residual disease in acute lymphoblastic leukemia Leukemia 2000 14: 1426–1435

    CAS  PubMed  Google Scholar 

  40. Biondi A, Valsecchi MG, Seriu T, D'Aniello E, Willemse MJ, Fasching K, Pannunzio A, Gadner H, Schrappe M, Kamps WA, Bartram CR, van Dongen JJM, Panzer-Grümayer ER . Molecular detection of minimal residual disease is a strong predictive factor of relapse in childhood B-lineage acute lymphoblastic leukemia with medium risk features. A case control study of the International BFM study group Leukemia 2000 14: 1939–1943

    CAS  PubMed  Google Scholar 

  41. Eckert C, Landt O, Taube T, Seeger K, Beyermann B, Proba J, Henze G . Potential of lightCycler technology for quantification of minimal residual disease in childhood acute lymphoblastic leukemia Leukemia 2000 14: 316–323

    CAS  PubMed  Google Scholar 

  42. Chen J-S, Coustan-Smith E. Suzuki T, Neale GA, Mihara K, Pui C-H, Campana D . Novel markers of leukemia identified by comparative analysis of gene expression with cDNA arrays Blood (in press)

  43. Neale GAM, Coustan-Smith E, Pan Q, Chen X, Gruhn B, Stow P, Behm FG, Pui C-H, Campana D . Tandem application of flow cytometry and polymerase chain reaction for comprehensive detection of minimal residual disease in childhood acute lymphoblastic leukemia Leukemia 1999 13: 1221–1226

    CAS  PubMed  Google Scholar 

  44. Coustan-Smith E, Sancho J, Hancock ML, Boyett JM, Behm FG, Raimondi SC, Sandlund JT, Rivera GK, Rubnitz JE, Ribeiro RC, Pui C-H, Campana D . Clinical importance of minimal residual disease in childhood acute lymphoblastic leukemia Blood 2000 96: 2691–2696

    CAS  PubMed  Google Scholar 

  45. Pui C-H, Campana D . New definition of remission in childhood acute lymphoblastic leukemia Leukemia 2000 14: 783–785

    CAS  PubMed  Google Scholar 

  46. Pui C-H . Risk assessment in ALL: beyond leukemia cell characteristics J Pediatr Hematol/Oncol (in press)

  47. Hurwitz CA, Silverman LB, Schorin MA, Clavell LA, Dalton VK, Glick KM, Gelber RD, Sallan SE . Substituting dexamethasone for prednisone complicates remission induction in children with acute lymphoblastic leukemia Cancer 2000 88: 1964–1969

    CAS  PubMed  Google Scholar 

  48. Voerman AJP, Hählen K, Kamps WA, Van Leeuwen EF, De Vaan GAM, Solbu G. Suciu S, Van Wering ER. Van der Does-Van den Berg A . High cure rate with a moderately intensive treatment regimen in non-high-risk childhood acute lymphoblastic leukemia: results of protocol ALL VI from the Dutch Childhood Leukemia Study Group J Clin Oncol 1996 14: 911–918

    Google Scholar 

  49. Mattano LA Jr, Sather HN, Trigg ME, Nachman JB . Osteonecrosis as a complication of treating acute lymphoblastic leukemia in children: a report from the Children's Cancer Group J Clin Oncol 2000 18: 3262–3272

    PubMed  Google Scholar 

  50. Schrappe M, Reiter A, Ludwig, W-D, Harbott J, Zimmermann M, Hiddemann W, Niemeyer C, Henze G, Feldges A, Zinti F, Kornhuber B, Ritter J, Welte K, Gardner H, Riehm H, for the German-Austrian-Swiss ALL-BFM Study Group . Improved outcome in childhood acute lymphoblastic leukemia despite reduced use of anthracyclines and cranial radiotherapy: results of trial ALL-BFM 90 Blood 2000 95: 3310–3322

    CAS  PubMed  Google Scholar 

  51. Meikle AW, Tyler FH . Potency and duration of action of glucocorticoids. Effects of hydrocortisone, prednisone and dexamethasone on human pituitary-adrenal function Am J Med 1977 63: 200–207

    CAS  PubMed  Google Scholar 

  52. Hirano T, Oka K, Takeuchi H, Sakurai E, Matsuno N, Tamaki T, Kozaki M . Clinical significance of glucocorticoid pharmacodynamics assessed by antilymphocyte action in kidney transplantation. Marked difference between prednisolone and methylprednisolone Transplantation 1994 57: 1341–1348

    CAS  PubMed  Google Scholar 

  53. Kuehl P, Zhang J, Lin Y, Watkins P, Maurel P, Daly AK, Wrighton SA, Hall S, Relling MV, Scheutz JD, Brimer C, Yasuda K, Strom S, Thummel KE, Schuetz EC, Boguski M . The CYP3A promoters: DNA sequence diversity and concordance of one allele with polymorphic CYP3A5 expression Nat Genet (in press)

  54. Hill FGH, Vergha-Khadem F, Gibson B, Hann I, Eden T, Richards S . UKALL XI randomised trial stratified CNS treatments and prospective neuropsychological assessment in childhood acute lymphoblastic leukemia (ALL) Blood 2000 90: (Suppl. 1) 466a

    Google Scholar 

  55. Conter V, Schrappe M, Arieó M, Reiter A, Rizzari C, Dördelmann M, Valsecchi MG, Zimmerman M, Ludwig W-D, Basso G, Masera G, Riehm H for the Associazione Italiana Ematologia Oncologia Pediatrica and the Berlin-Frankfurt-Monster Groups . Role of cranial radiotherapy for childhood T-cell acute lymphoblastic leukemia with high WBC count and good response to prednisone J Clin Oncol 1997 15: 2786–2791

    CAS  PubMed  Google Scholar 

  56. Faderl S, Talpaz M, Estrov Z, O'Brien S, Kurzrock R, Kantarjian HM . The biology of chronic myeloid leukemia N Engl J Med 1999 341: 164–172

    CAS  PubMed  Google Scholar 

  57. Beran M, Cao X, Estrov A, Jeha S, Jin G, O'Brien S, Talpaz M, Arlinghaus RB, Lydon NB, Kantarjian H . Selective inhibition of cell proliferation and BCR-ABL phosphorylation in acute lymphoblastic leukemia cells expressing MR 190,000 BCR-ABL protein by a tyrosine kinase inhibitor (CGP-57148) Clin Cancer Res 1998 4: 1661–1672

    CAS  PubMed  Google Scholar 

  58. Buchdunger E, Peng B, Ford J, Capdeville R, Resta D, Druker B, Sawyer C, Talpaz M . STI571, a molecularly targeted treatment modality for CML Proc 11thNCI-EORTC Symposium on New Drugs in Cancer Therapy 2000 (Abstr 044:

  59. Hochstrasser M . Ubiquitin-dependent protein degradation Annu Rev Genet 1996 30: 405–439

    CAS  PubMed  Google Scholar 

  60. Kordes U, Krappmann D, Heissmeyer V, Ludwig WD, Scheidereit C . Transcription factor NF-κB is constitutively activated in acute lymphoblastic leukemia cells Leukemia 2000 14: 399–402

    CAS  PubMed  Google Scholar 

  61. Adams J, Palombella VJ, Sausville EA, Johnson J, Destree A, Lazarus DD, Maas J . Ven CS, Prakash S, Elliett PJ. Proteasome inhibitors: a novel class of potent an effective antitumor agents Cancer Res 1999 59: 2615–2622

    CAS  PubMed  Google Scholar 

  62. Wong HL, Mazzola LM, Lazarus DD, Pien CS, Adams J, Elliott PJ . Proteasome inhibitors as new anti-cancer agents: biological activity and in vivo detection assay Proc Am Assoc Cancer Res 1998 39: 225

    Google Scholar 

  63. Adams J, Palombella VJ, Elliott PJ . Proteasome inhibition: a new strategy in cancer treatment Invest New Drugs 2000 18: 109–121

    CAS  PubMed  Google Scholar 

  64. Teicher B, Ara G, Herbst R . Palombella VJ, Adams J. The proteasome inhibitor PS-341 in cancer therapy Clin Cancer Res 1999 5: 2638–2645

    CAS  PubMed  Google Scholar 

  65. Aghajanian C, Elliott P, Adams J, Soignet S, Spriggs DR . Phase I trial of the proteasome inhibitor PS-341 in advanced malignancy Proc Am Soc Clin Oncol 2000 19: 189a

    Google Scholar 

  66. Papandreou C, Pagliaro L, Millikan R, Daliani DD, Herrmann JL, Yang H, Smith M, Adams J, Elliot P, Pien C, Newman RA, Lugothetis CJ . Phase I study of PS-34, a novel proteasome inhibitor, in patients with advanced malignancies Proc Am Soc Clin Oncol 2000 19: 190a

    Google Scholar 

  67. Senderowicz AM, Sausville EA . Preclinical and clinical development of cyclin-dependent kinase modulators (see comments) J Natl Cancer Inst 2000 92: 376–387

    CAS  PubMed  Google Scholar 

  68. Bunch RT, Eastman A . Enhancement of cisplatin-induced cytotoxicity by 7-hydroxystaurosporine (UCN-01), a new G2-checkpoint inhibitor Clin Cancer Res 1996 2: 791–797

    CAS  PubMed  Google Scholar 

  69. Jones CB, Clements MK, Wasi S, Daoud SS . Enhancement of camptothecin-induced cytotoxicity with UCN-01 in breast cancer cells: abrogation of S/G(2) arrest Cancer Chemother Pharmacol 2000 45: 252–258

    CAS  PubMed  Google Scholar 

  70. Omura-Minamisawa M, Diccianni MB, Batova A, Chang RC, Bridgeman LJ, Yu J, deWit E, Kung FH, Pullen JD, Yu HL . In vitro sensitivity of T-cell lymphoblastic leukemia to UNC-01 (7-hydroxystaurosporine) is dependent on p16 protein status: a Pediatric Oncology Group study Cancer Res 2000 60: 6573–6576

    CAS  PubMed  Google Scholar 

  71. Fuse E, Tanii H, Takai K, Asanome K, Kurata N, Kobayashi H, Kuwabara T, Kobayashi S, Sugiyama Y . Altered pharmacokinetics of a novel anticancer drug, UCN-01, caused by specific high affinity binding to α1-acid glycoprotein in humans Cancer Res 1999 59: 1054–1060

    CAS  PubMed  Google Scholar 

  72. Wang S, Vrana JA, Bartimole TM, Freemerman AJ, Jarvis WD, Kramer LB, Krystal G, Dent P, Grant S . Agents that down-regulate or inhibit protein kinase C circumvent resistance to 1-beta-D-arabinofuranosylcytosine-induced apoptosis in human leukemia cells that overexpress Bcl-2 Mol Pharmacal 1997 52: 1000–1009

    CAS  Google Scholar 

  73. Antonsson B, Martinou JC . The Bcl-2 protein family Exp Cell Res 2000 256: 50–57

    CAS  PubMed  Google Scholar 

  74. Cotter FE, Johnson P, Hall P, Pocock C, Al Mahdi N, Cowell TK, Morgan G . Antisense oligonucleotides suppress B-cell lymphoma growth in a SCID-hu mouse model Oncogene 1994 9: 3049–3055

    CAS  PubMed  Google Scholar 

  75. Keith FJ, Bradbury DA, Zhu YM, Russell NH . Inhibition of bcl-2 with antisense oligonucleotides induces apoptosis and increases the sensitivity of AML blasts to Ara-C Leukemia 1995 9: 131–138

    CAS  PubMed  Google Scholar 

  76. Konopleva M, Tari AM, Estrov Z, Harris D, Xie Z, Zhao S, Lopez-Berestein G, Adreff M . Liposomal Bcl-2 antisense oligonucleotides enhance proliferation, sersitize acute myeloid leukemia to cytosine-arabinoside, and induce apoptosis independent of other antiapoptotic proteins Blood 2000 95: 3929–3938

    CAS  PubMed  Google Scholar 

  77. Maung ZT, MacLean FR, Reid MM, Pearson ADJ, Proctor SJ, Hamilton PJ, Hall AG . The relationship between bcl-2 expression and response to chemotherapy in acute leukaemia Br J Haematol 1994 88: 105–109

    CAS  PubMed  Google Scholar 

  78. Uckun FM, Yang Z, Sather H, Steinherz P, Nachman J, Bostrom B, Croty L, Sarquis M, Ek O, Zeren T, Tubergen D, Reaman G, Gaynon P . Cellular expression of antiapoptotic PCL-2 oncoprotein in newly diagnosed childhood acute lymphoblastic leukemia: a Children's Cancer Group Study Blood 1997 89: 3769–3777

    CAS  PubMed  Google Scholar 

  79. Coustan-Smith E, Kitanaka A, Pui CH, McNinch L, Evans WE, Raimondi SC, Behm FG, Aricò M, Campana D . Clinical relevance of BCL-2 overexpression in childhood acute lymphoblastic leukemia Blood 1996 87: 1140–1146

    CAS  PubMed  Google Scholar 

  80. Salomons GS, Smets LA, Verwijs-Janssen M, Hart AAM, Haarman EG, Kaspers GJL, Van Wering ER, Van der Does-Van den Berg A, Kamps WA . Bcl-2 family members in childhood acute lymphoblastic leukemia: relationships with features at presentation, in vitro and in vivo drug response and long-term clinical outcome Leukemia 1999 13: 1574–1580

    CAS  PubMed  Google Scholar 

  81. Hale G, Xia MQ, Tighe HP, Dyer MJ, Waldmann H . The CAMPATH-1 antigen (CDw52) Tissue Antigens ??037 35: 118–127

    CAS  PubMed  Google Scholar 

  82. Xia MQ, Hale G, Waldmann H . Efficient complement-mediated lysis of cells containing the CAMPATH-1 (CDw52) antigen Mol Immunol 1993 30: 1089–1096

    CAS  PubMed  Google Scholar 

  83. Rowan W, Tite J, Topley P, Brett SJ . Cross-linking of the CAMPATH-1 antigen (CD52) mediates growth inhibition in human B- and T-lymphoma cell lines, and subsequent emergence of CD52-deficient cells Immunology 1998 95: 427–436

    CAS  PubMed  PubMed Central  Google Scholar 

  84. Flynn JM, Byrd JC . Campath-1H monoclonal antibody therapy Curr Opin Oncol 2000 12: 574–581

    CAS  PubMed  Google Scholar 

  85. Dyer MJ . The role of CAMPATH-1 antibodies in the treatment of lymphoid malignancies Semin Oncol 1999 26: 52–57

    CAS  PubMed  Google Scholar 

  86. Osterborg A, Dyer MJ, Bunjes D, Pangalis GA, Bastion Y, Catovsky D, Mellstedt H . Phase II multicenter study of human CD52 antibody in previously treated chronic lymphocytic leukemia. European Study Group of CAMPATH-1H treatment in chronic lymphocytic leukemia J Clin Oncol 1997 15: 1567–1574

    CAS  PubMed  Google Scholar 

  87. Kolitz J, O'Mara V, Willemze R, Poynton CH, Jaeger U, Brody J, Schulman P . Treatment of acute lymphoblastic leukemia (ALL) with CAMPATH-1H: initial observations Blood 1994 84: 301a

    Google Scholar 

  88. Lundin J, Österborg A, Brittinger G, Crowther D, Dombret H, Engert A, Epenetos A, Gisselbrecht C, Huhn D, Jaeger U, Thomas J, Marcus R, Nissen N, Poynton C, Rankin E, Stahel R, UppenKamp M, Willemze R, Mellstedt H . CAMPATH-1H monoclonal antibody in therapy for previously treated low-grade non-Hodgkin's lymphomas: a phase II multicenter study. European Study Group of CAMPATH-1H treatment in low-grade non-Hodgkin's lymphoma J Clin Oncol 1998 16: 3257–3263

    CAS  PubMed  Google Scholar 

  89. Jabado N, Le Deist F, Cant A, DeGraeff-Meeders ER, Fasth A, Morgan G, Vellodi A, Pale G, Bujan W, Thomas C, Cavazzana-Calvo M, Wijdenes J, Fischer A . Bone marrow transplantation from genetically HLA-nonidentical donors in children with fatal inherited disorders excluding severe combined immunodeficiencies: use of two monoclonal antibodies to prevent grant rejection Pediatrics 1996 98: 420–428

    CAS  PubMed  Google Scholar 

Download references

Acknowledgements

This workshop was made possible by unrestricted educational grants from the Glaxo Wellcome, Amgen, Sanofi-Synthelabo, Nabi and Ipsen Ltd Corporations. Preparation of the meeting report was supported by grants CA21765, CA36401, CA51001, CA60419, NIH/NIGMS Pharmacogenetics Research Network and Database (U01GM61374, http://pharmgkb.org/) under grant GM61393, and CA78224, by a Center of Excellence grant from the State of Tennessee, and by the American Lebanese Syrian Associated Charities (ALSAC).

Author information

Authors and Affiliations

  1. St Jude Children's Research Hospital and University of Tennessee, Memphis, TN, USA

    C-H Pui, MV Relling & WE Evans

  2. College of Medicine, Memphis, TN, USA

    C-H Pui

  3. Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA

    S Sallan

  4. Children's Hospital, Harvard Medical School, Boston, MA, USA

    S Sallan

  5. College of Pharmacy, Memphis, TN, USA

    MV Relling & WE Evans

  6. Department of Pediatrics, University of Milan-Bicocca, Ospedale San Gerardo, Monza, Italy

    G Masera

Authors
  1. C-H Pui
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. S Sallan
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. MV Relling
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. G Masera
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. WE Evans
    View author publications

    You can also search for this author in PubMed Google Scholar

Appendix: Participating groups/institutions (participants)

Appendix: Participating groups/institutions (participants)

Associazione Italiana di Ematologia ed Oncologia Pediatrica

(M Arico, G Basso, A Biondi, G Masera, MG Valsecchi)

Berlin-Frankfurt-Münster

(A Borkhardt, H Gadner, O Haas, J Harbott, H Riehm, M Schrappe)

Children's Oncology Group

(B Camitta, P Gaynon, J Nachman, J Pullen, J Shuster)

Cooperative Acute Lymphoblastic Leukemia

(G Janka-Schaub)

Dana Farber Cancer Institute

(S Sallan, L Silverman)

Dutch Childhood Leukemia Study Group

(R Pieters, A Veerman)

European Organization for Research and Treatment of Cancer – Childhood Leukemia Cooperative Group

(E Vilmer)

French Acute Lymphoblastic Leukemia Study Group

(A Baruchel)

Medical Research Council, United Kingdom Acute Lymphoblastic Leukemia

(JM Chessells, OB Eden)

Nordic Society of Paediatric Haematology and Oncology

(K Schmiegelow)

St Jude Children's Research Hospital

(J Boyett, D Campana, WE Evans, R Handgretinger, P Harrison, C-H Pui, MV Relling, JT Sandlund)

United States National Cancer Institute

(B Anderson)

Rights and permissions

Reprints and permissions

About this article

Cite this article

Pui, CH., Sallan, S., Relling, M. et al. International childhood Acute Lymphoblastic Leukemia workshop: Sausalito, CA, 30 November–1 December 2000. Leukemia 15, 707–715 (2001). https://doi.org/10.1038/sj.leu.2402111

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.leu.2402111

Keywords

This article is cited by

Search

Advanced search

Quick links